Carroll Financial Associates Inc. maintained its stake in Stryker Corporation (NYSE:SYK) during the second quarter, Holdings Channel reports. The institutional investor owned 1,486 shares of the medical technology company’s stock at the end of the second quarter. Carroll Financial Associates Inc.’s holdings in Stryker Corporation were worth $206,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after buying an additional 21,140,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after buying an additional 1,161,688 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Stryker Corporation by 41.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock worth $184,759,000 after buying an additional 414,715 shares in the last quarter. SG Americas Securities LLC boosted its position in Stryker Corporation by 600.6% in the first quarter. SG Americas Securities LLC now owns 412,340 shares of the medical technology company’s stock worth $54,285,000 after buying an additional 353,486 shares in the last quarter. Finally, Morgan Stanley boosted its position in Stryker Corporation by 17.9% in the first quarter. Morgan Stanley now owns 2,144,472 shares of the medical technology company’s stock worth $282,320,000 after buying an additional 325,661 shares in the last quarter. 73.79% of the stock is owned by institutional investors.

Stryker Corporation (NYSE:SYK) traded down 0.07% during mid-day trading on Wednesday, reaching $147.34. 340,861 shares of the company traded hands. The firm has a market capitalization of $55.11 billion, a price-to-earnings ratio of 32.89 and a beta of 0.80. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84. The stock’s 50 day moving average price is $144.07 and its 200 day moving average price is $136.07.

Stryker Corporation (NYSE:SYK) last released its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.98 billion. During the same period last year, the business earned $1.39 earnings per share. The business’s revenue was up 6.1% on a year-over-year basis. Equities analysts forecast that Stryker Corporation will post $6.50 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be issued a dividend of $0.425 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.15%. Stryker Corporation’s payout ratio is 37.95%.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/carroll-financial-associates-inc-continues-to-hold-position-in-stryker-corporation-syk/1496100.html.

SYK has been the subject of a number of research analyst reports. Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Morgan Stanley reaffirmed an “overweight” rating and issued a $160.00 price target (up previously from $155.00) on shares of Stryker Corporation in a report on Monday, July 10th. Cantor Fitzgerald initiated coverage on shares of Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price target for the company. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a report on Monday, July 17th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $140.00 price target (up previously from $135.00) on shares of Stryker Corporation in a report on Wednesday, April 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. Stryker Corporation currently has a consensus rating of “Hold” and a consensus price target of $144.03.

In other news, insider David Floyd sold 19,305 shares of Stryker Corporation stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total transaction of $2,790,730.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now owns 88,207 shares of the company’s stock, valued at $12,909,976.52. The disclosure for this sale can be found here. Insiders have sold 32,810 shares of company stock valued at $4,754,958 over the last quarter. Company insiders own 7.40% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.